Elisabeth Bendstrup

A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease : comorbidity and mortality. / Hyldgaard, Charlotte; Hilberg, Ole; Pedersen, Alma Becic; Ulrichsen, Sinna Pilgaard; Løkke, Anders; Bendstrup, Elisabeth; Ellingsen, Torkell.

In: Annals of the Rheumatic Diseases, Vol. 76, No. 10, 10.2017, p. 1700-1706.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{04b61493ba254bdba880bbeb91fd22db,
title = "A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality",
abstract = "OBJECTIVES: To compare mortality risks in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD) and patients with RA without ILD.DESIGN: Matched cohort study.SETTING: The study was conducted in Denmark, using nationwide, prospectively collected data.PARTICIPANTS: Among patients with RA diagnosed between 2004 and 2016, 679 patients with RA-ILD were matched for birth year, gender and age at RA diagnosis with 11 722 patients with RA but without ILD MAIN OUTCOME MEASURES: Mortality risks were assessed using Kaplan-Meier mortality curves, and hazard rate ratios (HRRs) for death were estimated using Cox proportional hazards regression models.RESULTS: The number of prevalent RA patients more than doubled from 15 352 to 35 362 individuals during the study period. RA-ILD was seen in 2.2% of incident RA patients. 34.0% of RA-ILD cases were diagnosed within 1 year prior to and 1 year after the RA diagnosis. One-year mortality was 13.9% (95% CI, 11.4% to 16.7%) in RA-ILD and 3.8% (95% CI, 3.5% to 4.2%) in non-ILD RA, 5-year mortality was 39.0% (34.4% to 43.5%) and 18.2% (17.3% to 19.1%) and 10-year mortality was 60.1% (52.9% to 66.5%) and 34.5% (32.8% to 36.1%), respectively. The HRRs for death were 2 to 10 times increased for RA-ILD compared with non-ILD RA, irrespective of follow-up period. Stratified analysis showed that the HRR for death was highest in the first months after the diagnosis of RA-ILD was made, especially in patients diagnosed with RA before diagnosis of ILD. HRR was higher in males and in patients without comorbidity as assessed by the Charlson Comorbidity Index.CONCLUSIONS: ILD is a serious complication in RA, with a significantly increased mortality compared with a large matched cohort of RA comparisons without ILD.",
keywords = "Journal Article",
author = "Charlotte Hyldgaard and Ole Hilberg and Pedersen, {Alma Becic} and Ulrichsen, {Sinna Pilgaard} and Anders L{\o}kke and Elisabeth Bendstrup and Torkell Ellingsen",
note = "{\textcopyright} Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.",
year = "2017",
month = oct,
doi = "10.1136/annrheumdis-2017-211138",
language = "English",
volume = "76",
pages = "1700--1706",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "B M J Group",
number = "10",

}

RIS

TY - JOUR

T1 - A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease

T2 - comorbidity and mortality

AU - Hyldgaard, Charlotte

AU - Hilberg, Ole

AU - Pedersen, Alma Becic

AU - Ulrichsen, Sinna Pilgaard

AU - Løkke, Anders

AU - Bendstrup, Elisabeth

AU - Ellingsen, Torkell

N1 - © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

PY - 2017/10

Y1 - 2017/10

N2 - OBJECTIVES: To compare mortality risks in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD) and patients with RA without ILD.DESIGN: Matched cohort study.SETTING: The study was conducted in Denmark, using nationwide, prospectively collected data.PARTICIPANTS: Among patients with RA diagnosed between 2004 and 2016, 679 patients with RA-ILD were matched for birth year, gender and age at RA diagnosis with 11 722 patients with RA but without ILD MAIN OUTCOME MEASURES: Mortality risks were assessed using Kaplan-Meier mortality curves, and hazard rate ratios (HRRs) for death were estimated using Cox proportional hazards regression models.RESULTS: The number of prevalent RA patients more than doubled from 15 352 to 35 362 individuals during the study period. RA-ILD was seen in 2.2% of incident RA patients. 34.0% of RA-ILD cases were diagnosed within 1 year prior to and 1 year after the RA diagnosis. One-year mortality was 13.9% (95% CI, 11.4% to 16.7%) in RA-ILD and 3.8% (95% CI, 3.5% to 4.2%) in non-ILD RA, 5-year mortality was 39.0% (34.4% to 43.5%) and 18.2% (17.3% to 19.1%) and 10-year mortality was 60.1% (52.9% to 66.5%) and 34.5% (32.8% to 36.1%), respectively. The HRRs for death were 2 to 10 times increased for RA-ILD compared with non-ILD RA, irrespective of follow-up period. Stratified analysis showed that the HRR for death was highest in the first months after the diagnosis of RA-ILD was made, especially in patients diagnosed with RA before diagnosis of ILD. HRR was higher in males and in patients without comorbidity as assessed by the Charlson Comorbidity Index.CONCLUSIONS: ILD is a serious complication in RA, with a significantly increased mortality compared with a large matched cohort of RA comparisons without ILD.

AB - OBJECTIVES: To compare mortality risks in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD) and patients with RA without ILD.DESIGN: Matched cohort study.SETTING: The study was conducted in Denmark, using nationwide, prospectively collected data.PARTICIPANTS: Among patients with RA diagnosed between 2004 and 2016, 679 patients with RA-ILD were matched for birth year, gender and age at RA diagnosis with 11 722 patients with RA but without ILD MAIN OUTCOME MEASURES: Mortality risks were assessed using Kaplan-Meier mortality curves, and hazard rate ratios (HRRs) for death were estimated using Cox proportional hazards regression models.RESULTS: The number of prevalent RA patients more than doubled from 15 352 to 35 362 individuals during the study period. RA-ILD was seen in 2.2% of incident RA patients. 34.0% of RA-ILD cases were diagnosed within 1 year prior to and 1 year after the RA diagnosis. One-year mortality was 13.9% (95% CI, 11.4% to 16.7%) in RA-ILD and 3.8% (95% CI, 3.5% to 4.2%) in non-ILD RA, 5-year mortality was 39.0% (34.4% to 43.5%) and 18.2% (17.3% to 19.1%) and 10-year mortality was 60.1% (52.9% to 66.5%) and 34.5% (32.8% to 36.1%), respectively. The HRRs for death were 2 to 10 times increased for RA-ILD compared with non-ILD RA, irrespective of follow-up period. Stratified analysis showed that the HRR for death was highest in the first months after the diagnosis of RA-ILD was made, especially in patients diagnosed with RA before diagnosis of ILD. HRR was higher in males and in patients without comorbidity as assessed by the Charlson Comorbidity Index.CONCLUSIONS: ILD is a serious complication in RA, with a significantly increased mortality compared with a large matched cohort of RA comparisons without ILD.

KW - Journal Article

U2 - 10.1136/annrheumdis-2017-211138

DO - 10.1136/annrheumdis-2017-211138

M3 - Journal article

C2 - 28611082

VL - 76

SP - 1700

EP - 1706

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 10

ER -